Loading
ADRA1A (Alpha-1A adrenergic receptor) is a receptor that reads hormone signals inside the cell nucleus. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours and Prostate cancer.
Alpha-1 adrenergic receptors are G protein-coupled receptors for catecholamines that signal through the G(q) family of G proteins, including G(q) and G(11). Upon activation, they stimulate the phosphatidylinositol-calcium second messenger pathway, leading to calcium release from intracellular stores and activation of protein kinase C. ADRA1A binds the catecholamine ligands norepinephrine and epinephrine.
Open Targets scores its association with cancer at 0.58 (direct and indirect evidence; datatypes literature 0.40, genetic association 0.29, clinical 0.86).
In plain words · ADRA1A (Alpha-1A adrenergic receptor) is a receptor that reads hormone signals inside the cell nucleus. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours and Prostate cancer.
ADRA1A (Alpha-1A adrenergic receptor) is a receptor that reads hormone signals inside the cell nucleus. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours and Prostate cancer.
Alpha-1 adrenergic receptors are G protein-coupled receptors for catecholamines that signal through the G(q) family of G proteins, including G(q) and G(11).
No product in this corpus aims at ADRA1A yet. Drugs cut off the hormone supply, block the receptor so the hormone cannot bind, or send the receptor to the cell's waste disposal.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA ADRA1A: RNA tissue enhanced (adipose tissue 21 nTPM, liver 56 nTPM); high antibody staining in 1 normal tissue. Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Neuroendocrine tumours, Prostate cancer); Open Targets associates it with 2 specific cancer types at or above 0.5 (benign prostatic hyperplasia, adrenal gland pheochromocytoma). (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas ADRA1A tissue; Open Targets ENSG00000120907 associations
First described 1993. Earliest sequence paper UniProt cites for the protein: Hirasawa et al, Biochem. Biophys. Res. Commun, 1993, "Cloning, functional expression and tissue distribution of human cDNA for the alpha 1C-adrenergic receptor". Source.
Sources: HGNC HGNC:277 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P35348 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000120907 (association with cancer (MONDO_0004992) 0.58; per-cancer scores at or above 0.5: prostate cancer 0.50, neuroendocrine neoplasm 0.51 (GraphQL API, CC0))
Alpha-1 adrenergic receptors are G protein-coupled receptors for catecholamines that signal through the G(q) family of G proteins, including G(q) and G(11). Upon activation, they stimulate the phosphatidylinositol-calcium second messenger pathway, leading to calcium release from intracellular stores and activation of protein kinase C. ADRA1A binds the catecholamine ligands norepinephrine and epinephrine. Can also couple to G(14) protein. Nuclear ADRA1A forms heterooligomers with ADRA1B to regulate phenylephrine(PE)-stimulated ERK signalling in cardiac myocytes. At the plasma membrane, ADRA1A interacts with CAVIN4/MURC to regulates ERK activation in cardiomyocytes, contributing to the regulation of cardiac hypertrophy. Location: Nucleus membrane; Cell membrane; Cytoplasm; Membrane, caveola (UniProt). Locus 8p21.2 (HGNC).
RNA: tissue enhanced (adipose tissue 21 nTPM, liver 56 nTPM), detected in many normal tissues.
Medium: Cerebral cortex, Hippocampus.
RNA cancer enhanced: Liver Hepatocellular Carcinoma 3 pTPM, Prostate Adenocarcinoma 2 pTPM.
No cancer sample stained medium or high.
HPA ADRA1A tissue · HPA ADRA1A pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"ADRA1A" OR ABSTRACT:"ADRA1A" OR TITLE:"adrenoceptor alpha 1A" OR ABSTRACT:"adrenoceptor alpha 1A" OR TITLE:"Alpha-1A adrenergic receptor" OR ABSTRACT:"Alpha-1A adrenergic receptor" OR TITLE:"ADRA1L1" OR ABSTRACT:"ADRA1L1" OR TITLE:"ADRA1C" OR ABSTRACT:"ADRA1C") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ADRA1A, not a curated reading list.